Abstract
A major change in the treatment of patients with multiple myeloma (MM) occurred with the discovery of new therapeutic agents (thalidomide, lenalidomide and bortezomib). However, MM still remains an incurable disease. Thus, a better understanding of the molecular processes involved in the genesis and progression of this disease is essential for the development of novel drug combinations th…